Vericel (VCEL) Q4 2024 earnings summary

Executive summary

• Achieved record financial and business results in 2024, with total revenue up 20% to $237.2 million and strong operating cash flow; Q4 revenue reached $75.4 million, up 16% year-over-year.

• Net income for 2024 was $10.4 million, reversing a prior year loss; Q4 net income grew 52% to $19.8 million.

• Adjusted EBITDA for the year increased 58% to $53.4 million, with Q4 adjusted EBITDA margin reaching 40%.

• Ended 2024 with $167 million in cash, restricted cash, and investments, and no debt.

• Key milestones included FDA approval and launch of MACI Arthro, pediatric indication for NexoBrid, and completion of a new headquarters and manufacturing facility.

Financial highlights

• Full-year gross margin improved to 73%, up 390–400 basis points year-over-year; Q4 gross margin reached a record 78%.

• MACI revenue increased 20% to $197.3 million; Burn Care revenue rose 22% to $39.9 million.

• Operating cash flow for 2024 was $58.2 million; Q4 operating cash flow was $22.2 million.

• Diluted EPS for 2024 was $0.20, compared to a loss of $0.07 in 2023; Q4 diluted EPS was $0.38, up from $0.26 in Q4 2023.

• Total operating expenses for 2024 were $167.6 million, up from $142.0 million in 2023, mainly due to increased headcount and sales/marketing for MACI Arthro.

Outlook and guidance

• 2025 revenue expected to grow 20–23%, with gross margin of 73–74% and adjusted EBITDA margin of 25–26%.

• Midterm targets updated: gross margin in the high 70% range and adjusted EBITDA margin in the high 30% range by 2029.

• MACI revenue growth projected in the low 20% range, with continued momentum from MACI Arthro but no significant change in trend assumed in guidance.

• Burn Care revenue expected to progress, with NexoBrid in the high single-digit million range and Epicel growth in the high single-digit percent range, mainly from price increases.

• Operating expenses for 2025 expected at $195 million, including $10 million incremental facility costs; CapEx to decrease significantly after H1 2025.